It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Integrating epigenetic data with genome-wide association study (GWAS) results can reveal disease mechanisms. The genome sequence itself also shapes the epigenome, with CpG density and transcription factor binding sites (TFBSs) strongly encoding the DNA methylome. Therefore, genetic polymorphism impacts on the observed epigenome. Furthermore, large genetic variants alter epigenetic signal dosage. Here, we identify DNA methylation variability between GWAS-SNP risk and non-risk haplotypes. In three subsets comprising 3128 MeDIP-seq peripheral-blood DNA methylomes, we find 7173 consistent and functionally enriched Differentially Methylated Regions. 36.8% can be attributed to common non-SNP genetic variants. CpG-SNPs, as well as facilitative TFBS-motifs, are also enriched. Highlighting their functional potential, CpG-SNPs strongly associate with allele-specific DNase-I hypersensitivity sites. Our results demonstrate strong DNA methylation allelic differences driven by obligatory or facilitative genetic effects, with potential direct or regional disease-related repercussions. These allelic variations require disentangling from pure tissue-specific modifications, may influence array studies, and imply underestimated population variability in current reference epigenomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Gao, Fei 2 ; Yuan, Wei 3 ; Roos, Leonie 4
; Acton, Richard J 5
; Xia, Yudong 2 ; Bell, Jordana 6 ; Ward, Kirsten 6 ; Mangino, Massimo 6
; Hysi, Pirro G 6
; Wang, Jun 7 ; Spector, Timothy D 6 1 Department of Twin Research & Genetic Epidemiology, King’s College London, London, UK; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; Epigenomic Medicine, Biological Sciences, Faculty of Environmental and Natural Sciences, University of Southampton, Southampton, UK; Human Development and Health Academic Unit, Institute of Developmental Sciences, University of Southampton, Southampton, UK
2 BGI-Shenzhen, Shenzhen, China
3 Department of Twin Research & Genetic Epidemiology, King’s College London, London, UK; Institute of Cancer Research, Sutton, UK
4 Department of Twin Research & Genetic Epidemiology, King’s College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK
5 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; Epigenomic Medicine, Biological Sciences, Faculty of Environmental and Natural Sciences, University of Southampton, Southampton, UK; Human Development and Health Academic Unit, Institute of Developmental Sciences, University of Southampton, Southampton, UK
6 Department of Twin Research & Genetic Epidemiology, King’s College London, London, UK
7 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK




